0001209191-22-025469.txt : 20220422
0001209191-22-025469.hdr.sgml : 20220422
20220422200415
ACCESSION NUMBER: 0001209191-22-025469
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220420
FILED AS OF DATE: 20220422
DATE AS OF CHANGE: 20220422
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Valliant John
CENTRAL INDEX KEY: 0001813574
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 22847099
MAIL ADDRESS:
STREET 1: FUSION PHARMACEUTICALS INC.
STREET 2: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001805890
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
BUSINESS PHONE: 289-799-0891
MAIL ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-20
0
0001805890
Fusion Pharmaceuticals Inc.
FUSN
0001813574
Valliant John
C/O FUSION PHARMACEUTICALS, INC.
2 INTERNATIONAL PLACE, SUITE 2310
BOSTON
MA
02110
1
1
0
0
Chief Executive Officer
Common Stock
2022-04-20
4
S
0
367
6.02
D
327763
D
Common Stock
2022-04-21
4
S
0
922
6.01
D
326841
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.02 to $6.03 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.00 to $6.05 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
/s/Maria Stahl as Attorney-in-Fact for John Valliant
2022-04-22